Oct. 24, 2023 |
|
Feb. 04, 2025 |
|
jRCT1031230422 |
Single-center exploratory study: Evaluation of therapeutic impact GLP-1 a gonist on glucose and lipid metabolism and fatty liver disease in obesity u sing genomic information |
|
Clinical study to clarify the effect of GLP-1 on metabolic improvement bas ed on genetic background |
Kitamoto Takumi |
||
Chiba University Hospital |
||
1-8-1, Inohana, Chuo-ku, Chiba-city, Chiba |
||
+81-432227171 |
||
t.kitamoto@chiba-u.jp |
||
Kitamoto Takumi |
||
Chiba University Hospital |
||
1-8-1, Inohana, Chuo-ku, Chiba-city, Chiba |
||
+81-432227171 |
||
t.kitamoto@chiba-u.jp |
Recruiting |
Oct. 24, 2023 |
||
50 | ||
Interventional |
||
single arm study |
||
open(masking not used) |
||
uncontrolled control |
||
single assignment |
||
diagnostic purpose |
||
1) Obese patients with a BMI of 30.0 kg/m2 or higher who have glucose intolerance, dyslipidemia, and fatty liver disease, as defined by the Japan Society for the Study of Obesity |
||
Persons who meet any of the following conditions are not eligible |
||
18age old over | ||
75age old not | ||
Both |
||
Obesity |
||
Patients with severe obesity who are undergoing lifestyle interventions such as diet and exercise will be treated with either tirzepatide or semaglutide, GLP-1-related drugs that have been proven effective for weight loss and are approved as reimbursement drugs in Japan, and observed for 12 months. Obesity-related diseases will be diagnosed at the beginning of the intervention (glucose intolerance, dyslipidemia, fatty liver, hypertension, hyperuricemia, and obesity-related kidney disease). |
||
Obesity, diabetes, dyslipidemia, Non-alcoholic ste atohepatitis |
||
D009765 |
||
Relevance of HbA1c changed at 12 months (%) to genotype |
||
Secondary efficacy outcomes |
Clinical Reseach Initiation-Fund (of Chiba University Hospital) | |
Not applicable |
Chiba University Certified Clinical Research Review Board | |
1-8-1, Inohana, Chuo-ku, Chiba-city, Chiba, Chiba, Chiba | |
+81-43-226-2616 |
|
prc-jim@chiba-u.jp | |
Approval | |
Sept. 19, 2023 |
No |
|
none |